Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion

Drug Metabolism and Disposition

Volumn 34, Issue 5, 2006, Pages 775-782

  Eriksson, Ulf G ^a   Dorani, Hassan ^a   Karlsson, Johan ^a   Fritsch, Holger ^a   Hoffmann, Kurt Jürgen ^a   Olsson, Lis ^a   Sarich, Troy C ^a,b   Wall, Ulrika ^a   Schützer, Kajs Marie ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; GLYCOPROTEIN P; MELAGATRAN; XIMELAGATRAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CELL LINE; CELL STRAIN CACO 2; CONFIDENCE INTERVAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXCRETION; DRUG TOLERABILITY; DRUG TRANSPORT; FEMALE; HUMAN; IN VITRO STUDY; MALE; NONHUMAN; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; STATISTICAL SIGNIFICANCE; VOLUNTEER;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; AZETIDINES; BENZYLAMINES; BILE; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CELL LINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; HUMANS; MALE; P-GLYCOPROTEIN; PARTIAL THROMBOPLASTIN TIME; QUINIDINE; RATS; RATS, SPRAGUE-DAWLEY; VERAPAMIL;

EID: 33645798633     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.008607     Document Type: Article

References (30)

1. Bergsrud EA and Gandhi PJ (2003) A review of the clinical uses of ximelagatran in thrombosis syndromes. J Thromb Thrombolysis 16:175-188.
2. Blondeau JM (2002) The evolution and role of macrolides in infectious diseases. Expert Opin Pharmacother 3:1131-1151.
3. Boos CJ and More RS (2004) Anticoagulation for non-valvular atrial fibrillation - towards a new beginning with ximelagatran. Curr Control Trials Cardiovasc Med 5:3.
4. Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, Larsson M, and Eriksson UG (2003) Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 42:765-777.
5. Dahl OE, Eriksson BI, Agnelli G, Cohen AT, Mouret P, Rosencher N, Panfilov S, Bylock A, and Andersson M (2005) Postoperative melagatran/ ximelagatran for the prevention of venous thromboembolism following major elective orthopaedic surgery. Effects of timing of first dose and risk factors for thromboembolism and bleeding complications on efficacy and safety. Clin Drug Investig 25:65-77.
6. Donnan GA, Dewey HM, and Chambers BR (2004) Warfarin for atrial fibrillation: the end of an era? Lancet Neurol 3:305-308.
7. Dresser GK, Spence JD, and Bailey DG (2000) Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57.
8. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalebo P, Panfilov S, Eskilson C, et al.; EXPRESS Study Group (2003a) The direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: The METHRO III study. J Thromb Haemostasis 1:2490-2496.
9. Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, and Schulman S (2003b) A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemostasis 1:41-47.
10. Eriksson UG, Bredberg U, Gislen K, Johansson LC, Frison L, Ahnoff M, and Gustafsson D (2003c) Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 59:35-43.
11. Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislen K, Fager G, and Gustafsson D (2003d) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 31:294-305.
12. Francis CS (2004) Ximelagatran: a new oral anticoagulant. Best Pract Res Clin Haematol 17:139-152.
13. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, and Colwell CW Jr; EXULT A Study Group (2003) Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 349:1703-1712.
14. Gustafsson D and Elg M (2003) The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 109:S9-S15.
15. Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, and Eriksson UG (2003) Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 42:381-392.
16. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationships between substrates and inhibitors of human CYP3A4 and P-glycoprotein. Pharm Res (NY) 16:408-414.
17. Larsson M, Ahnoff M, Abrahamsson A, Logren U, Fakt C, Öhrman I, and Persson B-A (2003) Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran and the intermediate metabolites, in biological samples by liquid chromatographymass spectrometry. J Chromatogr B 783:335-347.
18. Lin JH and Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics. Clinical implications. Clin Pharmacokinet 42:59-98.
19. Olsson SB and Executive Steering Committee on behalf of the SPORTIF III Investigators (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691-1698.
20. Sarich TC, Johansson S, Schutzer KM, Wall U, Kessler E, Teng R, and Eriksson UG (2004a) The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. J Clin Pharmacol 44:388-393.
21. Sarich TC, Schutzer KM, Dorani H, Wall U, Kalies I, Ohlsson L, and Eriksson UG (2004b) No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. J Clin Pharmacol 44:928-934.
22. Sarich TC, Schutzer KM, Wollbratt M, Wall U, Kessler E, and Eriksson UG (2004c) No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. J Clin Pharmacol 44:935-941.
23. Schuetz EG, Yasuda K, Arimori K, and Schuetz JD (1998) Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch Biochem Biophys 350:340-347.
24. Schulman S, Wahlander K, Lundstrom T, Clason B, and Eriksson H; THRIVE III Investigators (2003) Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349:1713-1721.
25. Teng R, Sarich TC, Eriksson UG, Hamer JE, Gilette S, Schützer, Carlson GF, and Kowey P (2004) A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. J Clin Pharmacol 44:1063-1071.
26. Wacher VJ, Wu CY, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
27. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, and Bylock A; ESTEEM Investigators (2003) Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362:789-797.
28. Wolzt M, Wollbratt M, Svensson M, Wåhlander K, Grind M, and Eriksson UG (2003) Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur J Clin Pharmacol 59:537-543.
29. Yu DK (1999) The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39:1203-1211.
30. Zhang Y and Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159-168.